Adenovirus-mediated leptin expression normalises hypertension associated with diet-induced obesity

Journal of Neuroendocrinology

Volumn 22, Issue 3, 2010, Pages 175-180

  Zhang, W ^a,b,c   Telemaque, S ^a,d   Augustyniak, R A ^a,e   Anderson, P ^a,f   Thomas, G D ^a,b,g   An, J ^a,f   Wang, Z ^a,b   Newgard, C B ^a,b,f   Victor, R G ^a,b,g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Arterial blood pressure; Gene therapy; High fat diet; Hypertension; Leptin; Metabolic syndrome; Obesity; Recombinant adenovirus

Indexed keywords

ADENOVIRUS VECTOR; LEPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HORMONE BLOOD LEVEL; HYPERTENSION; LIPID DIET; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; VIRAL GENE DELIVERY SYSTEM; WEIGHT GAIN;

ADENOVIRIDAE; ANIMALS; DIETARY FATS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HYPERTENSION; LEPTIN; MALE; OBESITY; RATS; RATS, WISTAR;

EID: 77949287559     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2010.01953.x     Document Type: Article

References (35)

1. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100:270-278.
2. Dobbins RL, Szczepaniak LS, Zhang W, McGarry JD. Chemical sympathectomy alters regulation of body weight during prolonged ICV leptin infusion. Am J Physiol Endocrinol Metab 2003, 284:E778-E787.
3. Buettner R, Newgard CB, Rhodes CJ, O'Doherty RM. Correction of diet-induced hyperglycemia, hyperinsulinemia, and skeletal muscle insulin resistance by moderate hyperleptinemia. Am J Physiol Endocrinol Metab 2000, 278:E563-E569.
4. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995, 1:1155-1161.
5. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005, 54:2012-2018.
6. Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW, Magosin S, Marco C, Caro JF. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 1996, 97:1344-1347.
7. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 1999, 17:1949-1953.
8. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000, 105:1243-1252.
9. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002, 39:496-501.
10. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409-414.
11. Knight WD, Seth R, Boron J, Overton JM. Short-term physiological hyperleptinemia decreases arterial blood pressure. Regul Pept 2009, 154:60-68.
12. Silvani A, Bastianini S, Berteotti C, Franzini C, Lenzi P, Lo MartireV, Zoccoli G. Sleep modulates hypertension in leptin-deficient obese mice. Hypertension 2009, 53:251-255.
13. Wolk R, Somers VK. Leptin and vascular function: friend or foe? Eur Heart J 2006, 27:2263-2265.
14. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, Trimarco B. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000, 49:293-297.
15. Procopio C, Andreozzi F, Laratta E, Cassese A, Beguinot F, Arturi F, Hribal ML, Perticone F, Sesti G. Leptin-stimulated endothelial nitric-oxide synthase via an adenosine 5′-monophosphate-activated protein kinase/Akt signaling pathway is attenuated by interaction with C-reactive protein. Endocrinology 2009, 150:3584-3593.
16. Momin AU, Melikian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, El GamelA, Desai JB, Nelson T, Driver C, Sherwood RA, Kearney MT. Leptin is an endothelial-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur Heart J 2006, 27:2294-2299.
17. Beltowski J, Wojcicka G, Jamroz-Wisniewska A, Borkowska E. Role of PI3K and PKB/Akt in acute natriuretic and NO-mimetic effects of leptin. Regul Pept 2007, 140:168-177.
18. Trinh KY, O'Doherty RM, Anderson P, Lange AJ, Newgard CB. Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem 1998, 273:31615-31620.
19. Roberts CK, Vaziri ND, Liang KH, Barnard RJ. Reversibility of chronic experimental syndrome X by diet modification. Hypertension 2001, 37:1323-1328.
20. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 1994, 43:204-211.
21. Sikka G, Yang R, Reid S, Benjo A, Koitabashi N, Camara A, Baraban E, O'Donnell CP, Berkowitz DE, Barouch LA. Leptin is essential in maintaining normal vascular compliance independent of body weight. Int J Obes (Lond) 2010, 34:203-206.
22. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA 1997, 94:8878-8883.
23. Van HeekM, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997, 99:385-390.
24. Mark AL, Correia ML, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002, 20:1245-1250.
25. Rahmouni K, Haynes WG, Morgan DA, Mark AL. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension 2002, 39:486-490.
26. Saito Y, Nakao K, Nishimura K, Sugawara A, Okumura K, Obata K, Sonoda R, Ban T, Yasue H, Imura H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 1987, 76:115-124.
27. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, Heitjan DF, Katz SD. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A~double-blind, placebo-controlled, randomized crossover trial. Circulation 1996, 94:3184-3189.
28. Kitashiro S, Sugiura T, Takayama Y, Tsuka Y, Izuoka T, Tokunaga S, Iwasaka T. Long-term administration of atrial natriuretic peptide in patients with acute heart failure. J Cardiovasc Pharmacol 1999, 33:948-952.
29. Lanfear DE. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev 2008, 10.1007/s10741-008-9113-y, DOI
30. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006, 113:977-985.
31. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003, 41:1072-1079.
32. Tanida M, Iwashita S, Terui N, Ootsuka Y, Shu M, Kang D, Suzuki M. Effect of peripheral administration of leptin on the renal sympathetic nerve activity in high-fat diet-related hypertensive rats. Life Sci 2006, 78:1149-1154.
33. Thomas GD, Zhang W, Victor RG. Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension. JAMA 2001, 285:2055-2057.
34. Augustyniak RA, Thomas GD, Victor RG, Zhang W. Nitric oxide pathway as new drug targets for refractory hypertension. Curr Pharm Des 2005, 11:3307-3315.
35. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008, 105:14070-14075.